ClinicalTrials.gg
CompletedNCT05448651Updated Jan 3, 2025Results posted

Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics

A Phase 1 interventional study of UPB-101 and Placebo in Asthma, sponsored by Upstream Bio Inc.. Completed at 4 sites in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Upstream Bio Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.

Enrollment
313th of 427
32 · median 69
Started
2022
with 25 others
Phase 1
81 of 558
2 open now
Registered
460th of 558
by date

Among the 558 studies in Asthma with a site in United Kingdom, this one is the 313th largest by enrollment of the 427 interventional ones that give a count, is one of 26 that started in 2022, is one of 81 in phase 1, and was the 460th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Asthma with a site in United Kingdom, or all of them as a file.
02

Study summary

The goals of this clinical study were to assess the safety, tolerability, blood levels, and disease impact of UPB-101 when given to adults with mild asthma. Eligible participant were consecutively assigned to 1 of 3 to 5 planned treatment groups. Each treatment group consisted of 8 individuals, six of whom will received active drug (UPB-101) and 2 who received placebo. Neither the study doctors nor the participants knew which participants were assigned to active study drug and which were assigned to placebo. The study was performed at 4 experienced research sites in the United Kingdom.

Read the detailed description

This was a two-part phase 1b, multi-center randomized, double-blind (Investigator and Subject blinded; Sponsor unblinded), placebo-controlled, multiple ascending-dose study to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of UPB-101 administered subcutaneously (SC) to adult subjects with asthma.

The study consists of Part A and Part B. Part A included 3 cohorts with pre-set dosing regimens. Part B (optional) included up to 2 additional cohorts whose doses and dosing intervals decided based upon the safety, PK, and PD results from Part A (i.e., an adaptive design), as applicable. The regimens selected for Part B did not exceed the exposures (i.e., doses and/or dosing intervals) included in Part A. Eight subjects were randomized per cohort (6 active, 2 placebo). Thus, a total of 32 subjects were enrolled in the study with 24 subjects in Part A and 8 in Part B.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 60, and has physician-diagnosed asthma
  2. (BMI) between 18 and 35 kg/m2
  3. Blood eosinophil cell count ≥200 (OR ≥150 combined with fractional exhaled nitric oxide [a measure of lung airway inflammation] >25) at one screening visit and ≥150 at the other screening
  4. Agrees to follow the required techniques
  5. Female or male participant agrees not to donate eggs or sperm, respectively, for a period of 120 days after the last dose of the study drug
  6. Able to perform spirometry (breathing tests)
  7. Asthma and non-biologic asthma medication have been stable for the past 2 months

Exclusion criteria

Exclusion Criteria:

  1. Employee, consultant, and/or immediate family member of any person involved in the conduct of the study
  2. Previous exposure to the study drug or known allergy/sensitivity to any of its ingredients
  3. Pregnant or breastfeeding female
  4. Unable to fast and avoid strenuous exercise for 9 hours prior to each site visit
  5. Serious allergic reaction to any injected drug
  6. Significantly abnormal clinical laboratory test results or a significant medical condition
  7. Recently donated blood (including blood products) or experienced significant loss of blood
  8. Has pacemaker or a significantly abnormal
  9. An active or a serious infection in the past 8 weeks
  10. Poorly-controlled diabetes or abnormal kidney function
  11. Tests positive to illicit drugs or nicotine and cannot limit alcohol consumption
  12. Tests positive for antibodies (HIV), , antibodies, or tuberculosis
  13. Received any vaccine within the past month
  14. Received any therapies in the past
  15. Received an antibody or therapeutic biologic product in the last 6 months
  16. Received (other than inhaled) in the past 2 months
  17. Participated recently in a clinical study
  18. Current tobacco smokers or has smoked within the last year
  19. Tested positive for COVID-19 in the past month
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Active substance 1

    UPB-101 Cohort 1

    Drug: UPB-101 · Drug: Placebo

  • Experimental
    Active substance 2

    UPB-101 Cohort 2

    Drug: UPB-101 · Drug: Placebo

  • Experimental
    Active substance 3

    UPB-101 Cohort 3

    Drug: UPB-101 · Drug: Placebo

  • Experimental
    Active Substance 4

    UPB-101 Cohort 4

    Drug: UPB-101 · Drug: Placebo

Interventions

  • Subcutaneous injection

    Also known as: Formerly ASP7266

  • DrugPlacebo

    Subcutaneous injection

    Also known as: 0.9% saline solution

06

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent Adverse Events and Serious Adverse Events

    Overall Summary of Treatment-emergent Adverse Events (TEAEs) and Adverse Events (AEs) up to Week 24 (Safety Population)

    Time frame: Baseline through 24 weeks

Secondary outcomes

  1. Incidence of Anti-drug Antibodies

    Blood samples were analyzed for the presence of ADAs using validated assays. Low titer ADA responses were detected toward the end of the concentration vs time profile. There was no evident effect of ADAs on drug exposure and no immune-related adverse events

    Time frame: Baseline through Week 32

  2. Maximum Observed Concentration of UPB-101

    Blood samples were collected and analyzed using a validated assay to determine the Cmax (ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.

    Time frame: First Dose = Day 1. Last Dose = Baseline through 32 weeks.

  3. Time to Maximum Observed Concentration of UPB-101

    Blood samples were collected and analyzed using a validated assay to determine the Tmax (days) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.

    Time frame: Baseline through 32 weeks

  4. Area Under the Concentration-time Curve Under One Dosing Interval of UPB-101

    Blood samples were collected and analyzed using a validated assay to determine the AUClast (d.ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.

    Time frame: Baseline through 32 weeks

07

Results

Posted Jan 3, 2025

Participant flow

The study was conducted in 4 sites in the United Kingdom (UK).

Participant flow — Overall Study
MilestoneActive Substance 1Active Substance 2Active Substance 3Active Substance 4Placebo
Started66668
Completed66668
Not completed00000

Outcome measures

PrimaryNumber of Treatment-emergent Adverse Events and Serious Adverse Events

Overall Summary of Treatment-emergent Adverse Events (TEAEs) and Adverse Events (AEs) up to Week 24 (Safety Population)

Time frame:
Baseline through 24 weeks
Reported as:
Number · adverse events
Number of Treatment-emergent Adverse Events and Serious Adverse Events
adverse eventsActive Substance 1Active Substance 2Active Substance 3Active Substance 4Placebo
any TEAEs191712925
SAEs00000
SecondaryIncidence of Anti-drug Antibodies

Blood samples were analyzed for the presence of ADAs using validated assays. Low titer ADA responses were detected toward the end of the concentration vs time profile. There was no evident effect of ADAs on drug exposure and no immune-related adverse events

Time frame:
Baseline through Week 32
Reported as:
Count of participants · Participants
Incidence of Anti-drug Antibodies
ParticipantsActive Substance 1Active Substance 2Active Substance 3Active Substance 4Placebo
Incidence of Anti-drug Antibodies45120
SecondaryMaximum Observed Concentration of UPB-101

Blood samples were collected and analyzed using a validated assay to determine the Cmax (ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.

Time frame:
First Dose = Day 1. Last Dose = Baseline through 32 weeks.
Reported as:
Mean · ug/mL
Maximum Observed Concentration of UPB-101
ug/mLActive Substance 1Active Substance 2Active Substance 3Active Substance 4
Cmax after first dose8.82 ± 2.2521.8 ± 3.7832.4 ± 6.231.85 ± 0.602
Cmax after last dose16.3 ± 5.0341.8 ± 5.6933.8 ± 8.39—
SecondaryTime to Maximum Observed Concentration of UPB-101

Blood samples were collected and analyzed using a validated assay to determine the Tmax (days) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.

Time frame:
Baseline through 32 weeks
Reported as:
Median · days
Time to Maximum Observed Concentration of UPB-101
daysActive Substance 1Active Substance 2Active Substance 3Active Substance 4
Tmax after first dose6.98 (2.92 to 14.0)5.95 (2.77 to 13.9)6.93 (5.93 to 6.98)9.94 (2.90 to 20.9)
Tmax after last dose5.00 (2.99 to 7.04)3.94 (2.90 to 6.91)4.98 (2.91 to 13.9)—
SecondaryArea Under the Concentration-time Curve Under One Dosing Interval of UPB-101

Blood samples were collected and analyzed using a validated assay to determine the AUClast (d.ug/mL) of UPB-101. The pharmacokinetic (PK) parameters were estimated using non-compartmental analysis.

Time frame:
Baseline through 32 weeks
Reported as:
Mean · day*μg/mL
Area Under the Concentration-time Curve Under One Dosing Interval of UPB-101
day*μg/mLActive Substance 1Active Substance 2Active Substance 3Active Substance 4
AUClast after the first dose187 ± 40.8449 ± 1011220 ± 23673.4 ± 26.6
AUClast after the last dose613 ± 1151740 ± 4961420 ± 453—

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Substance 10/6 (0%)0/6 (0%)5/6 (83.3%)
Active Substance 20/6 (0%)0/6 (0%)6/6 (100%)
Active Substance 30/6 (0%)0/6 (0%)5/6 (83.3%)
Active Substance 40/6 (0%)0/6 (0%)3/6 (50%)
Placebo0/8 (0%)0/8 (0%)6/8 (75%)
Most frequent other events
Showing 10 of 48
Most frequent other events
EventActive Substance 1Active Substance 2Active Substance 3Active Substance 4Placebo
HeadacheNervous system disorders3/62/62/61/60/8
RhinitisInfections and infestations1/62/60/60/63/8
COVID-19Infections and infestations1/60/62/60/61/8
Viral upper respiratory tract infectionInfections and infestations0/60/62/60/60/8
NasopharyngitisInfections and infestations0/60/60/60/62/8
CoughRespiratory, thoracic and mediastinal disorders0/60/61/60/62/8
AsthmaRespiratory, thoracic and mediastinal disorders0/60/60/60/62/8
Ligament sprainInjury, poisoning and procedural complications0/60/60/60/62/8
Ear infectionInfections and infestations0/60/60/61/60/8
HordeolumInfections and infestations0/60/60/61/60/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active Substance 1Active Substance 2Active Substance 3Active Substance 4PlaceboTotal
Mean35.7 ± 10.3137.7 ± 8.8232.7 ± 9.5448.0 ± 5.2537.0 ± 11.4138.1 ± 10.22
Sex: Female, Male
Sex: Female, Male(Participants)Active Substance 1Active Substance 2Active Substance 3Active Substance 4PlaceboTotal
Female5422316
Male1244516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Substance 1Active Substance 2Active Substance 3Active Substance 4PlaceboTotal
Hispanic or Latino100012
Not Hispanic or Latino5666730
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active Substance 1Active Substance 2Active Substance 3Active Substance 4PlaceboTotal
American Indian or Alaska Native000000
Asian203005
Native Hawaiian or Other Pacific Islander000000
Black or African American010012
White4426723
More than one race000000
Unknown or Not Reported011002
Region of Enrollment
Region of Enrollment(participants)Active Substance 1Active Substance 2Active Substance 3Active Substance 4PlaceboTotal
United Kingdom6666832
BMI at Screening (kg/m2)
BMI at Screening (kg/m2)(kg/m^2)Active Substance 1Active Substance 2Active Substance 3Active Substance 4PlaceboTotal
Mean26.57 ± 3.02525.18 ± 2.07425.22 ± 2.84827.65 ± 2.51825.56 ± 3.11026.01 ± 2.784
08

Study locations

4 sites
  • Hammersmith Medicines Research
    London, United Kingdom
  • Queen Anne Street Medical Centre
    London, United Kingdom
  • Richmond Pharmacology
    London, United Kingdom
  • Medicines Evaluation Unit
    Manchester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Aug 2023, 13 months.

Results were first posted in Jan 2025, 1 year 4 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 13 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2022
First posted
Jul 7, 2022
StartActual
Jul 8, 2022
Primary completionActual
Aug 15, 2023
CompletionActual
Oct 5, 2023
Results first posted
Jan 3, 2025
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05448651
Lead sponsor
Upstream Bio Inc.
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Jul 8, 2022
Primary completion
Aug 15, 2023
Completion
Oct 5, 2023
Results posted
Jan 3, 2025
Last update
Jan 3, 2025

Study contacts

Sumathi Sivapalasingam, MD
study director · Upstream Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verekitug

Start the discussion